Glycorex Transplantation – removing antibodies from blood to improve transplantation and fight autoimmune diseases

Glycorex’s unique molecular level technology that specifically selects and removes antibodies in the blood has opened up ground-breaking treatments and solutions in healthcare. The company’s medical devices enable transplants across the blood groups saving lives and providing health economic benefits by increasing the number of transplants. The company’s technology to treat blood is applied in several health care settings and a new disruptive product has recently been launched with the potential to increase availability of blood plasma. Several new products for the treatment of autoimmune diseases are under development.

Glycorex Transplantation - removing antibodies from blood to improve transplantation and fight autoimmune diseases

In addition to kidney transplants, our product, Glycosorb® ABO, is used in several other types of transplants, such as liver, heart and stem cell transplants. More than 60 scientific papers with Glycosorb® ABO show excellent short- and long-term results fully comparable to blood group compatible transplants. Thanks to Glycosorb® ABO, blood group incompatible transplants are now routinely performed in many countries.

With our unique technology as a base, we are currently expanding into new interesting applications. In the area of transfusion medicine, we have recently launched a product intended to be used for donated plasma to produce universal blood plasma which can be given regardless of the recipient’s blood group, which means major improvements in logistics, safety and availability.
The focus of our development work is now to develop new treatments for severe autoimmune diseases. The closest to launch is a specific treatment for rheumatoid arthritis (RA) – a disease that has affected around five million people in Europe.

Glycorex Transplantation AB (publ) is based in Lund, Sweden, and its shares are listed on NGM – Main Regulated, Stockholm (NGM: GTAB B).

Glycorex Transplantation – removing antibodies from blood to improve transplantation and fight autoimmune diseases

More info : Glycorex Transplantation AB

Keywords : transplantation, autoimmune diseases, Rheumatoid Arthritis, antibodies hematology

Zenith Epigenetics – bromodomain inhibitors

Zenith Epigenetics is a biotech company developing bromodomain (BET) inhibitors for the treatment of cancer and autoimmune disorders. Zenith Epigenetics aims to become a leading epigenetic company translating bromodomain biology into impactful therapies.

Zenith Epigenetics – bromodomain inhibitors

Zenith Epigenetics

Continue reading